<DOC>
	<DOC>NCT00482612</DOC>
	<brief_summary>The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries relative to placebo.</brief_summary>
	<brief_title>Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<criteria>Has signed written informed consent after the scope and nature of the investigation was explained to them Has difficulty falling asleep, maintaining sleep or has early morning awakenings Significant medical or psychiatric illness causing sleep disturbances Has a history of bipolar disorder or family (immediate family) of suicide Has sleep disorder such as sleep related breathing disorder, restless leg syndrome, narcolepsy Has significant other medical illness such as acute or chronic pain, heart, kidney or liver disease within the last year Currently diagnosed or meets the criteria for Major Depressive Disorder (MDD) or has been treated for MDD with the last 2 years Substance abuse, excessive use of alcohol (as determined by the physician) or drug addiction within the last year.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>